Limiting spinal cord injury by pharmacological intervention

Handbook of Clinical Neurology

Volumn 109, Issue , 2012, Pages 463-484

  Priestley, John V ^a   Michael Titus, Adina T ^a   Tetzlaff, Wolfram ^b  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84867807348     PISSN: 00729752     EISSN: None     Source Type: Book Series    
DOI: 10.1016/B978-0-444-52137-8.00029-2     Document Type: Chapter

References (256)

1. Agrawal S.K., Fehlings M.G. Mechanisms of secondary injury to spinal cord axons in vitro: role of Na+,Na+-K+-ATPase, the N+-H+ exchanger, and the Na+-Ca2+ exchanger. J Neurosci 1996, 16:545-552.
2. Aimone J.B., Leasure J.L., Perreau V.M., et al. Spatial and temporal gene expression profiling of the contused rat spinal cord. Exp Neurol 2004, 189:204-221.
3. Alano C.C., Swanson R.A. Players in the PARP-1 cell-death pathway: JNK1 joins the cast. Trends Biochem Sci 2006, 31:309-311.
4. Alano C.C., Kauppinen T.M., Valls A.V., et al. Minocycline inhibits poly(ADP-ribose) polymerase-1 at nanomolar concentrations. Proc Natl Acad Sci U S A 2006, 103:9685-9690.
5. Anderson D.K., Braughler J.M., Hall E.D., et al. Effects of treatment with U-74006F on neurological outcome following experimental spinal cord injury. J Neurosurg 1988, 69:562-567.
6. Anderson D.K., Hall E.D., Braughler J.M., et al. Effect of delayed administration of U74006F (tirilazad mesylate) on recovery of locomotor function after experimental spinal cord injury. J Neurotrauma 1991, 8:187-192.
7. Andrabi S.A., Dawson T.M., Dawson V.L. Mitochondrial and nuclear cross talk in cell death: parthanatos. Ann N Y Acad Sci 2008, 1147:233-241.
8. Azbill R.D., Mu X., Springer J.E. Riluzole increases high-affinity glutamate uptake in rat spinal cord synaptosomes. Brain Res 2000, 871:175-180.
9. Bakshi R., Ni R.X., Faden A.I. N-methyl-d-aspartate (NMDA) and opioid receptors mediate dynorphin-induced spinal cord injury: behavioral and histological studies. Brain Res 1992, 580:255-264.
10. Banik N.L., Shields D.C., Ray S., et al. Role of calpain in spinal cord injury: effects of calpain and free radical inhibitors. Ann N Y Acad Sci 1998, 844:131-137.
11. Bao F., Dekaban G.A., Weaver L.C. Anti-CD11d antibody treatment reduces free radical formation and cell death in the injured spinal cord of rats. J Neurochem 2005, 94:1361-1373.
12. Bao F., Chen Y., Schneider K.A., et al. An integrin inhibiting molecule decreases oxidative damage and improves neurological function after spinal cord injury. Exp Neurol 2008, 214:160-167.
13. Barut S., Canbolat A., Bilge T., et al. Lipid peroxidation in experimental spinal cord injury: time-level relationship. Neurosurg Rev 1993, 16:53-59.
14. Bavetta S., Hamlyn P.J., Burnstock G., et al. The effects of FK506 on dorsal column axons following spinal cord injury in adult rats: neuroprotection and local regeneration. Exp Neurol 1999, 158:382-393.
15. Beattie M.S., Bresnahan J.C., Komon J., et al. Endogenous repair after spinal cord contusion injuries in the rat. Exp Neurol 1997, 148:453-463.
16. Berger J., Moller D.E. The mechanisms of action of PPARs. Annu Rev Med 2002, 53:409-435.
17. Blight A.R. Cellular morphology of chronic spinal cord injury in the cat: analysis of myelinated axons by line-sampling. Neurosci 1983, 10:521-543.
18. Blight A.R. Delayed demyelination and macrophage invasion: a candidate for secondary cell damage in spinal cord injury. Cent Nerv Syst Trauma 1985, 2:299-315.
19. Blight A. Mechanical factors in experimental spinal cord injury. J Am Paraplegia Soc 1988, 11:26-34.
20. Blight A.R., DeCrescito V. Morphometric analysis of experimental spinal cord injury in the cat: the relation of injury intensity to survival of myelinated axons. Neurosci 1986, 19:321-341.
21. Blondeau N., Widmann C., Lazdunski M., et al. Polyunsaturated fatty acids induce ischemic and epileptic tolerance. Neurosci 2002, 109:231-241.
22. Bracken M.B., Holford T.R. Effects of timing of methylprednisolone or naloxone administration on recovery of segmental and long-tract neurological function in NASCIS 2. J Neurosurg 1993, 79:500-507.
23. Bracken M.B., Shepard M.J., Collins W.F., et al. A randomized, controlled trial of methylprednisolone or naloxone in the treatment of acute spinal-cord injury. Results of the Second National Acute Spinal Cord Injury Study. N Engl J Med 1990, 322:1405-1411.
24. Bracken M.B., Shepard M.J., Holford T.R., et al. Administration of methylprednisolone for 24 or 48 hours or tirilazad mesylate for 48 hours in the treatment of acute spinal cord injury. Results of the Third National Acute Spinal Cord Injury Randomized Controlled Trial. National Acute Spinal Cord Injury Study. JAMA 1997, 277:1597-1604.
25. Bracken M.B., Shepard M.J., Holford T.R., et al. Methylprednisolone or tirilazad mesylate administration after acute spinal cord injury: 1-year follow up. Results of the Third National Acute Spinal Cord Injury Randomized Controlled Trial. J Neurosurg 1998, 89:699-706.
26. Brackett N.L., Ibrahim E., Krassioukov A., et al. Systemic naloxone infusion may trigger spasticity in patients with spinal cord injury: case series. J Spinal Cord Med 2007, 30:272-275.
27. Bramlett H.M. Sex differences and the effect of hormonal therapy on ischemic brain injury. Pathophysiology 2005, 12:17-27.
28. Brines M., Cerami A. Emerging biological roles for erythropoietin in the nervous system. Nat Rev Neurosci 2005, 6:484-494.
29. Brines M., Grasso G., Fiordaliso F., et al. Erythropoietin mediates tissue protection through an erythropoietin and common beta-subunit heteroreceptor. Proc Natl Acad Sci U S A 2004, 101:14907-14912.
30. Brook G.A., Plate D., Franzen R., et al. Spontaneous longitudinally orientated axonal regeneration is associated with the Schwann cell framework within the lesion site following spinal cord compression injury of the rat. J Neurosci Res 1998, 53:51-65.
31. Calder P.C. N-3 polyunsaturated fatty acids and inflammation: from molecular biology to the clinic. Lipids 2003, 38:343-352.
32. Carlson S.L., Parrish M.E., Springer J.E., et al. Acute inflammatory response in spinal cord following impact injury. Exp Neurol 1998, 151:77-88.
33. Casas C.E., Herrera L.P., Prusmack C., et al. Effects of epidural hypothermic saline infusion on locomotor outcome and tissue preservation after moderate thoracic spinal cord contusion in rats. J Neurosurg Spine 2005, 2:308-318.
34. Casella G.T., Marcillo A., Bunge M.B., et al. New vascular tissue rapidly replaces neural parenchyma and vessels destroyed by a contusion injury to the rat spinal cord. Exp Neurol 2002, 173:63-76.
35. Catania A. Neuroprotective actions of melanocortins: a therapeutic opportunity. Trends Neurosci 2008, 31:353-360.
36. Cayli S.R., Kocak A., Yilmaz U., et al. Effect of combined treatment with melatonin and methylprednisolone on neurological recovery after experimental spinal cord injury. Eur Spine J 2004, 13:724-732.
37. Celik M., Gokmen N., Erbayraktar S., et al. Erythropoietin prevents motor neuron apoptosis and neurologic disability in experimental spinal cord ischemic injury. Proc Natl Acad Sci U S A 2002, 99:2258-2263.
38. Chaovipoch P., Jelks K.A., Gerhold L.M., et al. 17beta-estradiol is protective in spinal cord injury in post- and pre-menopausal rats. J Neurotrauma 2006, 23:830-852.
39. Choo A.M., Liu J., Lam C.K., et al. Contusion, dislocation, and distraction: primary hemorrhage and membrane permeability in distinct mechanisms of spinal cord injury. J Neurosurg Spine 2007, 6:255-266.
40. Choo A.M., Liu J., Dvorak M., et al. Secondary pathology following contusion, dislocation, and distraction spinal cord injuries. Exp Neurol 2008, 212:490-506.
41. Clendenon N.R., Allen N., Gordon W.A., et al. Inhibition of Na+-K+-activated ATPase activity following experimental spinal cord trauma. J Neurosurg 1978, 49:563-568.
42. Constantini S., Young W. The effects of methylprednisolone and the ganglioside GM1 on acute spinal cord injury in rats. J Neurosurg 1994, 80:97-111.
43. Crowe M.J., Bresnahan J.C., Shuman S.L., et al. Apoptosis and delayed degeneration after spinal cord injury in rats and monkeys. Nat Med 1997, 3:73-76.
44. Crutcher K.A., Gendelman H.E., Kipnis J., et al. Debate: " is increasing neuroinflammation beneficial for neural repair?" J Neuroimmune Pharmacol 2006, 1:195-211.
45. Cuzzocrea S., Genovese T., Mazzon E., et al. Effect of 17beta-estradiol on signal transduction pathways and secondary damage in experimental spinal cord trauma. Shock 2008, 29:362-371.
46. Danielisova V., Chavko M. Comparative effects of the N-methyl-d-aspartate antagonist MK-801 and the calcium channel blocker KB-2796 on neurologic and metabolic recovery after spinal cord ischemia. Exp Neurol 1998, 149:203-208.
47. De Biase A., Knoblach S.M., Di Giovanni S., et al. Gene expression profiling of experimental traumatic spinal cord injury as a function of distance from impact site and injury severity. Physiol Genomics 2005, 22:368-381.
48. De Nicola A.F., Gonzalez S.L., Labombarda F., et al. Progesterone treatment of spinal cord injury: effects on receptors, neurotrophins, and myelination. J Mol Neurosci 2006, 28:3-15.
49. Dery M.A., Rousseau G., Benderdour M., et al. Atorvastatin prevents early apoptosis after thoracic spinal cord contusion injury and promotes locomotion recovery. Neurosci Lett 2009, 453:73-76.
50. Dietrich W.D. Therapeutic hypothermia for spinal cord injury. Crit Care Med 2009, 37:S238-S242.
51. Ditor D.S., Bao F., Chen Y., et al. A therapeutic time window for anti-CD 11d monoclonal antibody treatment yielding reduced secondary tissue damage and enhanced behavioral recovery following severe spinal cord injury. J Neurosurg Spine 2006, 5:343-352.
52. Doble A. The pharmacology and mechanism of action of riluzole. Neurology 1996, 47:S233-S241.
53. Donnelly D.J., Popovich P.G. Inflammation and its role in neuroprotection, axonal regeneration and functional recovery after spinal cord injury. Exp Neurol 2008, 209:378-388.
54. Duchemin A.M., Ren Q., Mo L., et al. GM1 ganglioside induces phosphorylation and activation of Trk and Erk in brain. J Neurochem 2002, 81:696-707.
55. Dumont R.J., Okonkwo D.O., Verma S., et al. Acute spinal cord injury, part I: pathophysiologic mechanisms. Clin Neuropharmacol 2001, 24:254-264.
56. Ehrenreich H., Hasselblatt M., Dembowski C., et al. Erythropoietin therapy for acute stroke is both safe and beneficial. Mol Med 2002, 8:495-505.
57. Emery E., Aldana P., Bunge M.B., et al. Apoptosis after traumatic human spinal cord injury. J Neurosurg 1998, 89:911-920.
58. Erbayraktar S., Grasso G., Sfacteria A., et al. Asialoerythropoietin is a nonerythropoietic cytokine with broad neuroprotective activity in vivo. Proc Natl Acad Sci U S A 2003, 100:6741-6746.
59. Esposito E., Genovese T., Caminiti R., et al. Melatonin regulates matrix metalloproteinases after traumatic experimental spinal cord injury. J Pineal Res 2008, 45:149-156.
60. Esposito E., Genovese T., Caminiti R., et al. Melatonin reduces stress-activated/mitogen-activated protein kinases in spinal cord injury. J Pineal Res 2009, 46:79-86.
61. Faden A.I., Jacobs T.P., Holaday J.W. Opiate antagonist improves neurologic recovery after spinal injury. Science 1981, 211:493-494.
62. Faden A.I., Molineaux C.J., Rosenberger J.G., et al. Endogenous opioid immunoreactivity in rat spinal cord following traumatic injury. Ann Neurol 1985, 17:386-390.
63. Faden A.I., Lemke M., Demediuk P. Effects of BW755C, a mixed cyclo-oxygenase-lipoxygenase inhibitor, following traumatic spinal cord injury in rats. Brain Res 1988, 463:63-68.
64. Faden A.I., Sacksen I., Noble L.J. Opiate-receptor antagonist nalmefene improves neurological recovery after traumatic spinal cord injury in rats through a central mechanism. J Pharmacol Exp Ther 1988, 245:742-748.
65. Farooqui A.A., Ong W.Y., Horrocks L.A., et al. Comparison of biochemical effects of statins and fish oil in brain: the battle of the titans. Brain Res Brain Res Rev 2007, 56:443-471.
66. Faulkner J.R., Herrmann J.E., Woo M.J., et al. Reactive astrocytes protect tissue and preserve function after spinal cord injury. J Neurosci 2004, 24:2143-2155.
67. Fee D.B., Swartz K.R., Joy K.M., et al. Effects of progesterone on experimental spinal cord injury. Brain Res 2007, 1137:146-152.
68. Festoff B.W., Ameenuddin S., Arnold P.M., et al. Minocycline neuroprotects, reduces microgliosis, and inhibits caspase protease expression early after spinal cord injury. J Neurochem 2006, 97:1314-1326.
69. Flamm E.S., Young W., Collins W.F., et al. A phase I trial of naloxone treatment in acute spinal cord injury. J Neurosurg 1985, 63:390-397.
70. Fleming J.C., Norenberg M.D., Ramsay D.A., et al. The cellular inflammatory response in human spinal cords after injury. Brain 2006, 129:3249-3269.
71. Fleming J.C., Bao F., Chen Y., et al. Alpha4beta1 integrin blockade after spinal cord injury decreases damage and improves neurological function. Exp Neurol 2008, 214:147-159.
72. Fraidakis M.J., Kiyotani T., Pernold K., et al. Recovery from spinal cord injury in tumor necrosis factor-alpha, signal transducers and activators of transcription 4 and signal transducers and activators of transcription 6 null mice. NeuroReport 2007, 18:185-189.
73. Friberg H., Ferrand-Drake M., Bengtsson F., et al. Cyclosporin A, but not FK 506, protects mitochondria and neurons against hypoglycemic damage and implicates the mitochondrial permeability transition in cell death. J Neurosci 1998, 18:5151-5159.
74. Fu Q., Hue J., Li S. Nonsteroidal anti-inflammatory drugs promote axon regeneration via RhoA inhibition. J Neurosci 2007, 27:4154-4164.
75. Fujimoto T., Nakamura T., Ikeda T., et al. Potent protective effects of melatonin on experimental spinal cord injury. Spine 2000, 25:769-775.
76. Geisler F.H., Dorsey F.C., Coleman W.P. Recovery of motor function after spinal cord injury - a randomized, placebo-controlled trial with GM-1 ganglioside. N Engl J Med 1991, 324:1829-1838.
77. Geisler F.H., Coleman W.P., Grieco G., et al. The Sygen multicenter acute spinal cord injury study. Spine 2001, 26:S87-S98.
78. Genovese T., Mazzon E., Muia C., et al. Attenuation in the evolution of experimental spinal cord trauma by treatment with melatonin. J Pineal Res 2005, 38:198-208.
79. Genovese T., Mazzon E., Muia C., et al. Inhibitors of poly(ADP-ribose) polymerase modulate signal transduction pathways and secondary damage in experimental spinal cord trauma. J Pharmacol Exp Ther 2005, 312:449-457.
80. Genovese T., Mazzon E., Crisafulli C., et al. Immunomodulatory effects of etanercept in an experimental model of spinal cord injury. J Pharmacol Exp Ther 2006, 316:1006-1016.
81. Genovese T., Mazzon E., Crisafulli C., et al. Effects of combination of melatonin and dexamethasone on secondary injury in an experimental mice model of spinal cord trauma. J Pineal Res 2007, 43:140-153.
82. Genovese T., Mazzon E., Crisafulli C., et al. TNF-alpha blockage in a mouse model of SCI: evidence for improved outcome. Shock 2008, 29:32-41.
83. Genovese T., Rossi A., Mazzon E., et al. Effects of zileuton and montelukast in mouse experimental spinal cord injury. Br J Pharmacol 2008, 153:568-582.
84. Gonzalez R., Hickey M.J., Espinosa J.M., et al. Therapeutic neutralization of CXCL10 decreases secondary degeneration and functional deficit after spinal cord injury in mice. Regen Med 2007, 2:771-783.
85. Gorio A., Gokmen N., Erbayraktar S., et al. Recombinant human erythropoietin counteracts secondary injury and markedly enhances neurological recovery from experimental spinal cord trauma. Proc Natl Acad Sci U S A 2002, 99:9450-9455.
86. Gris D., Marsh D.R., Oatway M.A., et al. Transient blockade of the CD11d/CD18 integrin reduces secondary damage after spinal cord injury, improving sensory, autonomic, and motor function. J Neurosci 2004, 24:4043-4051.
87. Gris D., Marsh D.R., Dekaban G.A., et al. Comparison of effects of methylprednisolone and anti-CD11d antibody treatments on autonomic dysreflexia after spinal cord injury. Exp Neurol 2005, 194:541-549.
88. Grossman S.D., Wolfe B.B., Yasuda R.P., et al. Changes in NMDA receptor subunit expression in response to contusive spinal cord injury. J Neurochem 2000, 75:174-184.
89. Grossman S.D., Rosenberg L.J., Wrathall J.R. Temporal-spatial pattern of acute neuronal and glial loss after spinal cord contusion. Exp Neurol 2001, 168:273-282.
90. Guest J.D., Hiester E.D., Bunge R.P. Demyelination and Schwann cell responses adjacent to injury epicenter cavities following chronic human spinal cord injury. Exp Neurol 2005, 192:384-393.
91. Guizar-Sahagun G., Rodriguez-Balderas C.A., Franco-Bourland R.E., et al. Lack of neuroprotection with pharmacological pretreatment in a paradigm for anticipated spinal cord lesions. Spinal Cord 2008, 47:156-160.
92. Guth L., Zhang Z., Roberts E. Key role for pregnenolone in combination therapy that promotes recovery after spinal cord injury. Proc Natl Acad Sci U S A 1994, 91:12308-12312.
93. Guven M.B., Cirak B., Yuceer N., et al. Is indomethacin harmful in spinal cord injury treatment? An experimental study. Pediatr Neurosurg 1999, 31:189-193.
94. Hadjiconstantinou M., Neff N.H. GM1 ganglioside: in vivo and in vitro trophic actions on central neurotransmitter systems. J Neurochem 1998, 70:1335-1345.
95. Hadjiconstantinou M., Yates A.J., Neff N.H. Hypoxia-induced neurotransmitter deficits in neonatal rats are partially corrected by exogenous GM1 ganglioside. J Neurochem 1990, 55:864-869.
96. Hadley M.N. Pharmacological therapy after acute cervical spinal cord injury. Neurosurgery 2002, 50:S63-S72.
97. Hains B.C., Waxman S.G. Activated microglia contribute to the maintenance of chronic pain after spinal cord injury. J Neurosci 2006, 26:4308-4317.
98. Hains B.C., Yucra J.A., Hulsebosch C.E. Reduction of pathological and behavioral deficits following spinal cord contusion injury with the selective cyclooxygenase-2 inhibitor NS-398. J Neurotrauma 2001, 18:409-423.
99. Halestrap A.P., Connern C.P., Griffiths E.J., et al. Cyclosporin A binding to mitochondrial cyclophilin inhibits the permeability transition pore and protects hearts from ischemia/reperfusion injury. Mol Cell Biochem 1997, 174:167-172.
100. Hall E.D., Braughler J.M. Role of lipid peroxidation in post-traumatic spinal cord degeneration: a review. Cent Nerv Syst Trauma 1986, 3:281-294.
101. Hall E.D., Wolf D.L. A pharmacological analysis of the pathophysiological mechanisms of posttraumatic spinal cord ischemia. J Neurosurg 1986, 64:951-961.
102. Hall E.D., Yonkers P.A. Preservation of motor nerve function during early degeneration by the 21-aminosteroid anti-oxidant U74006F. Brain Res 1990, 513:244-247.
103. Harada N., Taoka Y., Okajima K. Role of prostacyclin in the development of compression trauma-induced spinal cord injury in rats. J Neurotrauma 2006, 23:1739-1749.
104. Hauser K.F., Foldes J.K., Turbek C.S. Dynorphin A (1-13) neurotoxicity in vitro: opioid and non-opioid mechanisms in mouse spinal cord neurons. Exp Neurol 1999, 160:361-375.
105. Hawryluk G.W., Rowland J., Kwon B.K., et al. Protection and repair of the injured spinal cord: a review of completed, ongoing, and planned clinical trials for acute spinal cord injury. Neurosurg Focus 2008, 25:E14.
106. Hayashi Y., Shumsky J.S., Connors T., et al. Immunosuppression with either cyclosporine A or FK506 supports survival of transplanted fibroblasts and promotes growth of host axons into the transplant after spinal cord injury. J Neurotrauma 2005, 22:1267-1281.
107. Headrick J.P., Faden A.I., Vink R. Intrathecal dynorphin-A infusion in rat spinal cord causes energy depletion, edema and neurologic dysfunction. Neurochem Int 1995, 26:489-495.
108. Heller A.R., Rossler S., Litz R.J., et al. Omega-3 fatty acids improve the diagnosis-related clinical outcome. Crit Care Med 2006, 34:972-979.
109. Hengartner M.O. The biochemistry of apoptosis. Nature 2000, 407:770-776.
110. Heurteaux C., Laigle C., Blondeau N., et al. Alpha-linolenic acid and riluzole treatment confer cerebral protection and improve survival after focal brain ischemia. Neurosci 2006, 137:241-251.
111. Holmberg E., Zhang S.X., Sarmiere P.D., et al. Statins decrease chondroitin sulfate proteoglycan expression and acute astrocyte activation in central nervous system injury. Exp Neurol 2008, 214:78-86.
112. Holtz A., Gerdin B. Efficacy of the 21-aminosteroid U74006F in improving neurological recovery after spinal cord injury in rats. Neurol Res 1992, 14:49-52.
113. Horrocks L.A., Demediuk P., Saunders R.D., et al. The degradation of phospholipids, formation of metabolites of arachidonic acid, and demyelination following experimental spinal cord injury. Cent Nerv Syst Trauma 1985, 2:115-120.
114. Huang W.L., George K.J., Ibba V., et al. The characteristics of neuronal injury in a static compression model of spinal cord injury in adult rats. Eur J Neurosci 2007, 25:362-372.
115. Huang W.L., King V.R., Curran O.E., et al. A combination of intravenous and dietary docosahexaenoic acid significantly improves outcome after spinal cord injury. Brain 2007, 130:3004-3019.
116. Huang W., Bhavsar A., Ward R.E., et al. Arachidonyl trifluoromethyl ketone is neuroprotective after spinal cord injury. J Neurotrauma 2009, 26:1429-1434.
117. Hung K.S., Hwang S.L., Liang C.L., et al. Calpain inhibitor inhibits p35-p25-Cdk5 activation, decreases tau hyperphosphorylation, and improves neurological function after spinal cord hemisection in rats. J Neuropathol Exp Neurol 2005, 64:15-26.
118. Hurlbert R.J., Hamilton M.G. Methylprednisolone for acute spinal cord injury: 5-year practice reversal. Can J Neurol Sci 2008, 35:41-45.
119. Ibarra A., Diaz-Ruiz A. Protective effect of cyclosporin-A in spinal cord injury: an overview. Curr Med Chem 2006, 13:2703-2710.
120. Imaizumi T., Kocsis J.D., Waxman S.G. The role of voltage-gated Ca2+ channels in anoxic injury of spinal cord white matter. Brain Res 1999, 817:84-92.
121. Inamasu J., Nakamura Y., Ichikizaki K. Induced hypothermia in experimental traumatic spinal cord injury: an update. J Neurol Sci 2003, 209:55-60.
122. Jou I.M. Effects of core body temperature on changes in spinal somatosensory-evoked potential in acute spinal cord compression injury: an experimental study in the rat. Spine 2000, 25:1878-1885.
123. Kakulas B.A. A review of the neuropathology of human spinal cord injury with emphasis on special features. J Spinal Cord Med 1999, 22:119-124.
124. Kakulas B.A. The applied neuropathology of human spinal cord injury. Spinal Cord 1999, 37:79-88.
125. Kang C.B., Hong Y., Dhe-Paganon S., et al. FKBP family proteins: immunophilins with versatile biological functions. Neurosignals 2008, 16:318-325.
126. Kerr B.J., Patterson P.H. Leukemia inhibitory factor promotes oligodendrocyte survival after spinal cord injury. Glia 2005, 51:73-79.
127. Keswani S.C., Buldanlioglu U., Fischer A., et al. A novel endogenous erythropoietin mediated pathway prevents axonal degeneration. Ann Neurol 2004, 56:815-826.
128. Kigerl K.A., Gensel J.C., Ankeny D.P., et al. Identification of two distinct macrophage subsets with divergent effects causing either neurotoxicity or regeneration in the injured mouse spinal cord. J Neurosci 2009, 29:13435-13444.
129. Kim R.C. Pathology of non-neoplastic, regional disorders of the spinal cord. Principles and Practice of Neuropathology 2003, 459-496. Oxford University Press, Oxford. J.S. Nelson, H. Mena, J.E. Parisi (Eds.).
130. King V.R., Huang W.L., Dyall S.C., et al. Omega-3 fatty acids improve recovery, whereas omega-6 fatty acids worsen outcome, after spinal cord injury in the adult rat. J Neurosci 2006, 26:4672-4680.
131. Kiziltepe U., Turan N.N., Han U., et al. Resveratrol, a red wine polyphenol, protects spinal cord from ischemia-reperfusion injury. J Vasc Surg 2004, 40:138-145.
132. Koyanagi I., Tator C.H., Theriault E. Silicone rubber microangiography of acute spinal cord injury in the rat. Neurosurgery 1993, 32:260-268.
133. Kuchner E.F., Hansebout R.R., Pappius H.M. Effects of dexamethasone and of local hypothermia on early and late tissue electrolyte changes in experimental spinal cord injury. J Spinal Disord 2000, 13:391-398.
134. Kurt G., Ergun E., Cemil B., et al. Neuroprotective effects of infliximab in experimental spinal cord injury. Surg Neurol 2009, 71:332-336.
135. Kwon B.K., Tetzlaff W., Grauer J.N., et al. Pathophysiology and pharmacologic treatment of acute spinal cord injury. Spine J 2004, 4:451-464.
136. Kwon B.K., Mann C., Sohn H.M., et al. Hypothermia for spinal cord injury. Spine J 2008, 8:859-874.
137. Labombarda F., Gonzalez S.L., Lima A., et al. Effects of progesterone on oligodendrocyte progenitors, oligodendrocyte transcription factors, and myelin proteins following spinal cord injury. Glia 2009, 57:884-897.
138. Lang-Lazdunski L., Heurteaux C., Dupont H., et al. Prevention of ischemic spinal cord injury: comparative effects of magnesium sulfate and riluzole. J Vasc Surg 2000, 32:179-189.
139. Lang-Lazdunski L., Blondeau N., Jarretou G., et al. Linolenic acid prevents neuronal cell death and paraplegia after transient spinal cord ischemia in rats. J Vasc Surg 2003, 38:564-575.
140. Lasiene J., Shupe L., Perlmutter S., et al. No evidence for chronic demyelination in spared axons after spinal cord injury in a mouse. J Neurosci 2008, 28:3887-3896.
141. Lauritzen I., Blondeau N., Heurteaux C., et al. Polyunsaturated fatty acids are potent neuroprotectors. EMBO J 2000, 19:1784-1793.
142. Lee Y.L., Shih K., Bao P., et al. Cytokine chemokine expression in contused rat spinal cord. Neurochem Int 2000, 36:417-425.
143. Lee S.M., Yune T.Y., Kim S.J., et al. Minocycline reduces cell death and improves functional recovery after traumatic spinal cord injury in the rat. J Neurotrauma 2003, 20:1017-1027.
144. Leist M., Ghezzi P., Grasso G., et al. Derivatives of erythropoietin that are tissue protective but not erythropoietic. Science 2004, 305:239-242.
145. Liu D., Thangnipon W., McAdoo D.J. Excitatory amino acids rise to toxic levels upon impact injury to the rat spinal cord. Brain Res 1991, 547:344-348.
146. Liu X.Z., Xu X.M., Hu R., et al. Neuronal and glial apoptosis after traumatic spinal cord injury. J Neurosci 1997, 17:5395-5406.
147. Liu J.B., Tang T.S., Yang H.L., et al. Antioxidation of melatonin against spinal cord injury in rats. Chin Med J (Engl) 2004, 117:571-575.
148. Lo T.P., Cho K.S., Garg M.S., et al. Systemic hypothermia improves histological and functional outcome after cervical spinal cord contusion in rats. J Comp Neurol 2009, 514:433-448.
149. Lopez-Vales R., Garcia-Alias G., Fores J., et al. FK 506 reduces tissue damage and prevents functional deficit after spinal cord injury in the rat. J Neurosci Res 2005, 81:827-836.
150. Lopez-Vales R., Fores J., Navarro X., et al. Olfactory ensheathing glia graft in combination with FK506 administration promote repair after spinal cord injury. Neurobiol Dis 2006, 24:443-454.
151. Lopez-Vales R., Garcia-Alias G., Guzman-Lenis M.S., et al. Effects of COX-2 and iNOS inhibitors alone or in combination with olfactory ensheathing cell grafts after spinal cord injury. Spine 2006, 31:1100-1106.
152. Lou J., Lenke L.G., Ludwig F.J., et al. Apoptosis as a mechanism of neuronal cell death following acute experimental spinal cord injury. Spinal Cord 1998, 36:683-690.
153. McDonald J.W., Goldberg M.P., Gwag B.J., et al. Cyclosporine induces neuronal apoptosis and selective oligodendrocyte death in cortical cultures. Ann Neurol 1996, 40:750-758.
154. McTigue D.M., Tripathi R., Wei P., et al. The PPAR gamma agonist pioglitazone improves anatomical and locomotor recovery after rodent spinal cord injury. Exp Neurol 2007, 205:396-406.
155. Madsen J.R., MacDonald P., Irwin N., et al. Tacrolimus (FK506) increases neuronal expression of GAP-43 and improves functional recovery after spinal cord injury in rats. Exp Neurol 1998, 154:673-683.
156. Mann C., Lee J.H., Liu J., et al. Delayed treatment of spinal cord injury with erythropoietin or darbepoetin-a lack of neuroprotective efficacy in a contusion model of cord injury. Exp Neurol 2008, 211:34-40.
157. Mann C.M., Lee J.H., Hillyer J., et al. Lack of robust neurologic benefits with simvastatin or atorvastatin treatment after acute thoracic spinal cord contusion injury. Exp Neurol 2010, 221:285-295.
158. Mansson R., Hansson M.J., Morota S., et al. Re-evaluation of mitochondrial permeability transition as a primary neuroprotective target of minocycline. Neurobiol Dis 2007, 25:198-205.
159. Marchand F., Tsantoulas C., Singh D., et al. Effects of etanercept and minocycline in a rat model of spinal cord injury. Eur J Pain 2009, 13:673-681.
160. Mata de Urquiza A., Liu S., Sjoberg M., et al. Docosahexaenoic acid, a ligand for the retinoid X receptor in mouse brain. Science 2000, 290:2140-2144.
161. Michalik L., Wahli W. Involvement of PPAR nuclear receptors in tissue injury and wound repair. J Clin Invest 2006, 116:598-606.
162. Mobley L.W., Agrawal S.K. Role of calcineurin in calcium-mediated hypoxic injury to white matter. Spine J 2003, 3:11-18.
163. Mori T.A., Beilin L.J. Omega-3 fatty acids and inflammation. Curr Atheroscler Rep 2004, 6:461-467.
164. Nashmi R., Fehlings M.G. Changes in axonal physiology and morphology after chronic compressive injury of the rat thoracic spinal cord. Neurosci 2001, 104:235-251.
165. Nesic O., Lee J., Unabia G.C., et al. Aquaporin 1 - a novel player in spinal cord injury. J Neurochem 2008, 105:628-640.
166. Nogradi A., Szabo A., Pinter S., et al. Delayed riluzole treatment is able to rescue injured rat spinal motoneurons. Neurosci 2007, 144:431-438.
167. Norenberg M.D., Smith J., Marcillo A. The pathology of human spinal cord injury: defining the problems. J Neurotrauma 2004, 21:429-440.
168. Nottingham S., Knapp P., Springer J. FK506 treatment inhibits caspase-3 activation and promotes oligodendroglial survival following traumatic spinal cord injury. Exp Neurol 2002, 177:242-251.
169. Oatway M.A., Chen Y., Bruce J.C., et al. Anti-CD11d integrin antibody treatment restores normal serotonergic projections to the dorsal, intermediate, and ventral horns of the injured spinal cord. J Neurosci 2005, 25:637-647.
170. O'Collins V.E., Macleod M.R., Donnan G.A., et al. 1,026 experimental treatments in acute stroke. Ann Neurol 2006, 59:467-477.
171. Ozkisacik E.A., Discigil B., Boga M., et al. Effects of cyclosporin a on neurological outcome and serum biomarkers in the same setting of spinal cord ischemia model. Ann Vasc Surg 2006, 20:243-249.
172. Pannu R., Christie D.K., Barbosa E., et al. Post-trauma Lipitor treatment prevents endothelial dysfunction, facilitates neuroprotection, and promotes locomotor recovery following spinal cord injury. J Neurochem 2007, 101:182-200.
173. Panter S.S., Yum S.W., Faden A.I. Alteration in extracellular amino acids after traumatic spinal cord injury. Ann Neurol 1990, 27:96-99.
174. Pantovic R., Draganic P., Erakovic V., et al. Effect of indomethacin on motor activity and spinal cord free fatty acid content after experimental spinal cord injury in rabbits. Spinal Cord 2005, 43:519-526.
175. Park S.W., Yi J.H., Miranpuri G., et al. Thiazolidinedione class of peroxisome proliferator-activated receptor gamma agonists prevents neuronal damage, motor dysfunction, myelin loss, neuropathic pain, and inflammation after spinal cord injury in adult rats. J Pharmacol Exp Ther 2007, 320:1002-1012.
176. Peng X.M., Zhou Z.G., Glorioso J.C., et al. Tumor necrosis factor-alpha contributes to below-level neuropathic pain after spinal cord injury. Ann Neurol 2006, 59:843-851.
177. Pereira S., Zhou M., Mocsai A., et al. Resting murine neutrophils express functional alpha 4 integrins that signal through Src family kinases. J Immunol 2001, 166:4115-4123.
178. Pinzon A., Marcillo A., Pabon D., et al. A re-assessment of erythropoietin as a neuroprotective agent following rat spinal cord compression or contusion injury. Exp Neurol 2008, 213:129-136.
179. Pinzon A., Marcillo A., Quintana A., et al. A re-assessment of minocycline as a neuroprotective agent in a rat spinal cord contusion model. Brain Res 2008, 1243:146-151.
180. Plunet W.T., Streijger F., Lam C.K., et al. Dietary restriction started after spinal cord injury improves functional recovery. Exp Neurol 2008, 213:28-35.
181. Popovich P.G., Wei P., Stokes B.T. Cellular inflammatory response after spinal cord injury in Sprague-Dawley and Lewis rats. J Comp Neurol 1997, 377:443-464.
182. Popovich P.G., Guan Z., Wei P., et al. Depletion of hematogenous macrophages promotes partial hindlimb recovery and neuroanatomical repair after experimental spinal cord injury. Exp Neurol 1999, 158:351-365.
183. Profyris C., Cheema S.S., Zang D., et al. Degenerative and regenerative mechanisms governing spinal cord injury. Neurobiol Dis 2004, 15:415-436.
184. Qiao G.F., Cheng Z.F., Huo R., et al. GM1 ganglioside contributes to retain the neuronal conduction and neuronal excitability in visceral and baroreceptor afferents. J Neurochem 2008, 106:1637-1645.
185. Rabchevsky A.G., Fugaccia I., Sullivan P.G., et al. Cyclosporin A treatment following spinal cord injury to the rat: behavioral effects and stereological assessment of tissue sparing. J Neurotrauma 2001, 18:513-522.
186. Radojicic M., Reier P.J., Steward O., et al. Septations in chronic spinal cord injury cavities contain axons. Exp Neurol 2005, 196:339-341.
187. Rafati D.S., Geissler K., Johnson K., et al. Nuclear factor-kappaB decoy amelioration of spinal cord injury-induced inflammation and behavior outcomes. J Neurosci Res 2008, 86:566-580.
188. Ravikumar R., McEwen M.L., Springer J.E. Post-treatment with the cyclosporin derivative, NIM811, reduced indices of cell death and increased the volume of spared tissue in the acute period following spinal cord contusion. J Neurotrauma 2007, 24:1618-1630.
189. Ray S.K., Hogan E.L., Banik N.L. Calpain in the pathophysiology of spinal cord injury: neuroprotection with calpain inhibitors. Brain Res Rev 2003, 42:169-185.
190. Reiter R.J., Tan D.X., Manchester L.C., et al. Melatonin defeats neurally-derived free radicals and reduces the associated neuromorphological and neurobehavioral damage. J Physiol Pharmacol 2007, 58:5-22.
191. Resnick D.K., Graham S.H., Dixon C.E., et al. Role of cyclooxygenase 2 in acute spinal cord injury. J Neurotrauma 1998, 15:1005-1013.
192. Ritz M.F., Hausmann O.N. Effect of 17beta-estradiol on functional outcome, release of cytokines, astrocyte reactivity and inflammatory spreading after spinal cord injury in male rats. Brain Res 2008, 1203:177-188.
193. Saadoun S., Bell B.A., Verkman A.S., et al. Greatly improved neurological outcome after spinal cord compression injury in AQP4-deficient mice. Brain 2008, 131:1087-1098.
194. Sabel B.A., Gottlieb J., Schneider G.E. Exogenous GM1 gangliosides protect against retrograde degeneration following posterior neocortex lesions in developing hamsters. Brain Res 1988, 459:373-380.
195. Saganova K., Orendacova J., Cizkova D., et al. Limited minocycline neuroprotection after balloon-compression spinal cord injury in the rat. Neurosci Lett 2008, 433:246-249.
196. Salgado-Ceballos H., Guizar-Sahagun G., Feria-Velasco A., et al. Spontaneous long-term remyelination after traumatic spinal cord injury in rats. Brain Res 1998, 782:126-135.
197. Samantaray S., Sribnick E.A., Das A., et al. Melatonin attenuates calpain upregulation, axonal damage and neuronal death in spinal cord injury in rats. J Pineal Res 2008, 44:348-357.
198. Schengrund C.L. The role(s) of gangliosides in neural differentiation and repair: a perspective. Brain Res Bull 1990, 24:131-141.
199. Schumacher P.A., Siman R.G., Fehlings M.G. Pretreatment with calpain inhibitor CEP-4143 inhibits calpain I activation and cytoskeletal degradation, improves neurological function, and enhances axonal survival after traumatic spinal cord injury. J Neurochem 2000, 74:1646-1655.
200. Schumacher M., Guennoun R., Stein D.G., et al. Progesterone: therapeutic opportunities for neuroprotection and myelin repair. Pharmacol Ther 2007, 116:77-106.
201. Schwartz G., Fehlings M.G. Evaluation of the neuroprotective effects of sodium channel blockers after spinal cord injury: improved behavioral and neuroanatomical recovery with riluzole. J Neurosurg 2001, 94:245-256.
202. Senter H.J., Venes J.L. Loss of autoregulation and posttraumatic ischemia following experimental spinal cord trauma. J Neurosurg 1979, 50:198-206.
203. Serhan C.N., Arita M., Hong S., et al. Resolvins, docosatrienes, and neuroprotectins, novel omega-3-derived mediators, and their endogenous aspirin-triggered epimers. Lipids 2004, 39:1125-1132.
204. Sharma H.S., Nyberg F., Gordh T., et al. Topical application of dynorphin A (1-17) antibodies attenuates neuronal nitric oxide synthase up-regulation, edema formation, and cell injury following focal trauma to the rat spinal cord. Acta Neurochir Suppl 2006, 96:309-315.
205. Sharma H.S., Skottner A., Lundstedt T., et al. Neuroprotective effects of melanocortins in experimental spinal cord injury. An experimental study in the rat using topical application of compounds with varying affinity to melanocortin receptors. J Neural Transm 2006, 113:463-476.
206. Shin Y.C., Choi K.Y., Kim W.G. Cyclosporin A has a protective effect with induced upregulation of Hsp70 and nNOS on severe spinal cord ischemic injury in rabbits. J Invest Surg 2007, 20:113-120.
207. Shortland P.J., Leinster V.H., White W., et al. Riluzole promotes cell survival and neurite outgrowth in rat sensory neurones in vitro. Eur J Neurosci 2006, 24:3343-3353.
208. Simpkins J.W., Yang S.H., Sarkar S.N., et al. Estrogen actions on mitochondria - physiological and pathological implications. Mol Cell Endocrinol 2008, 290:51-59.
209. Simpson R.K., Baskin D.S., Dudley A.W., et al. The influence of long-term nifedipine or indomethacin therapy on neurologic recovery from experimental spinal cord injury. J Spinal Disord 1991, 4:420-427.
210. Sribnick E.A., Wingrave J.M., Matzelle D.D., et al. Estrogen attenuated markers of inflammation and decreased lesion volume in acute spinal cord injury in rats. J Neurosci Res 2005, 82:283-293.
211. Sribnick E.A., Matzelle D.D., Ray S.K., et al. Estrogen treatment of spinal cord injury attenuates calpain activation and apoptosis. J Neurosci Res 2006, 84:1064-1075.
212. Sroga J.M., Jones T.B., Kigerl K.A., et al. Rats and mice exhibit distinct inflammatory reactions after spinal cord injury. J Comp Neurol 2003, 462:223-240.
213. Stein D.G., Wright D.W., Kellermann A.L. Does progesterone have neuroprotective properties?. Ann Emerg Med 2008, 51:164-172.
214. Stirling D.P., Khodarahmi K., Liu J., et al. Minocycline treatment reduces delayed oligodendrocyte death, attenuates axonal dieback, and improves functional outcome after spinal cord injury. J Neurosci 2004, 24:2182-2190.
215. Stirling D.P., Koochesfahani K.M., Steeves J.D., et al. Minocycline as a neuroprotective agent. Neuroscientist 2005, 11:308-322.
216. Stirling D.P., Liu S., Kubes P., et al. Depletion of Ly6G/Gr-1 leukocytes after spinal cord injury in mice alters wound healing and worsens neurological outcome. J Neurosci 2009, 29:753-764.
217. Streit W.J., SempleRowland S.L., Hurley S.D., et al. Cytokine mRNA profiles in contused spinal cord and axotomized facial nucleus suggest a beneficial role for inflammation and gliosis. Exp Neurol 1998, 152:74-87.
218. Sturiale A., Campo S., Crasci E., et al. Erythropoietin and its lost receptor. Nephrol Dial Transplant 2007, 22:1484-1485.
219. Swartz K.R., Fee D.B., Joy K.M., et al. Gender differences in spinal cord injury are not estrogen-dependent. J Neurotrauma 2007, 24:473-480.
220. Taoka Y., Okajima K., Uchiba M., et al. Role of neutrophils in spinal cord injury in the rat. Neurosci 1997, 79:1177-1182.
221. Taskiran D., Tanyalcin T., Sozmen E.Y., et al. The effects of melatonin on the antioxidant systems in experimental spinal injury. Int J Neurosci 2000, 104:63-73.
222. Tator C.H. Update on the pathophysiology and pathology of acute spinal cord injury. Brain Pathol 1995, 5:407-413.
223. Tator C.H., Koyanagi I. Vascular mechanisms in the pathophysiology of human spinal cord injury. J Neurosurg 1997, 86:483-492.
224. Teng Y.D., Choi H., Onario R.C., et al. Minocycline inhibits contusion-triggered mitochondrial cytochrome c release and mitigates functional deficits after spinal cord injury. Proc Natl Acad Sci U S A 2004, 101:3071-3076.
225. Thomas A.J., Nockels R.P., Pan H.Q., et al. Progesterone is neuroprotective after acute experimental spinal cord trauma in rats. Spine 1999, 24:2134-2138.
226. Tirilazad International Steering Committee Tirilazad mesylate in acute ischemic stroke: a systematic review. Stroke 2000, 31:2257-2265.
227. Topsakal C., Kilic N., Ozveren F., et al. Effects of prostaglandin E1, melatonin, and oxytetracycline on lipid peroxidation, antioxidant defense system, paraoxonase (PON1) activities, and homocysteine levels in an animal model of spinal cord injury. Spine 2003, 28:1643-1652.
228. Totoiu M.O., Keirstead H.S. Spinal cord injury is accompanied by chronic progressive demyelination. J Comp Neurol 2005, 486:373-383.
229. Tureyen K., Kapadia R., Bowen K.K., et al. Peroxisome proliferator-activated receptor-gamma agonists induce neuroprotection following transient focal ischemia in normotensive, normoglycemic as well as hypertensive and type-2 diabetic rodents. J Neurochem 2007, 101:41-56.
230. Vitellaro-Zuccarello L., Mazzetti S., Madaschi L., et al. Erythropoietin-mediated preservation of the white matter in rat spinal cord injury. Neurosci 2007, 144:865-877.
231. Vitellaro-Zuccarello L., Mazzetti S., Madaschi L., et al. Chronic erythropoietin-mediated effects on the expression of astrocyte markers in a rat model of contusive spinal cord injury. Neurosci 2008, 151:452-466.
232. Voda J., Yamaji T., Gold B.G. Neuroimmunophilin ligands improve functional recovery and increase axonal growth after spinal cord hemisection in rats. J Neurotrauma 2005, 22:1150-1161.
233. Voda J., Hama A., Sagen J. FK506 reduces the severity of cutaneous hypersensitivity in rats with a spinal cord contusion. Neurosci Res 2007, 58:95-99.
234. Vorwerk C.K., Bonheur J., Kreutz M.R., et al. GM1 ganglioside administration protects spinal neurons after glutamate excitotoxicity. Restor Neurol Neurosci 1999, 14:47-51.
235. Vreugdenhil M., Bruehl C., Voskuyl R.A., et al. Polyunsaturated fatty acids modulate sodium and calcium currents in CA1 neurons. Proc Natl Acad Sci U S A 1996, 93:12559-12563.
236. Wahl F., Stutzmann J.M. Neuroprotective effects of riluzole in neurotrauma models: a review. Acta Neurochir Suppl (Wien) 1999, 73:103-110.
237. Walker J.B., Harris M. GM-1 ganglioside administration combined with physical therapy restores ambulation in humans with chronic spinal cord injury. Neurosci Lett 1993, 161:174-178.
238. Wang X., Zhao X., Mao Z.Y., et al. Neuroprotective effect of docosahexaenoic acid on glutamate-induced cytotoxicity in rat hippocampal cultures. NeuroReport 2003, 14:2457-2461.
239. Wang X., Budel S., Baughman K., et al. Ibuprofen enhances recovery from spinal cord injury by limiting tissue loss and stimulating axonal growth. J Neurotrauma 2009, 26:81-95.
240. Webb A.A., Chan C.B., Brown A., et al. Estrogen reduces the severity of autonomic dysfunction in spinal cord-injured male mice. Behav Brain Res 2006, 171:338-349.
241. Wells J.E., Hurlbert R.J., Fehlings M.G., et al. Neuroprotection by minocycline facilitates significant recovery from spinal cord injury in mice. Brain 2003, 126:1628-1637.
242. Winkler T., Sharma H.S., Stalberg E., et al. Naloxone reduces alterations in evoked potentials and edema in trauma to the rat spinal cord. Acta Neurochir Suppl (Wien) 1994, 60:511-515.
243. Woods A.S., Kaminski R., Oz M., et al. Decoy peptides that bind dynorphin noncovalently prevent NMDA receptor-mediated neurotoxicity. J Proteome Res 2006, 5:1017-1023.
244. Wrathall J.R., Teng Y.D., Choiniere D. Amelioration of functional deficits from spinal cord trauma with systemically administered NBQX, an antagonist of non-N-methyl-d-aspartate receptors. Exp Neurol 1996, 137:119-126.
245. Wu A., Ying Z., Gomez-Pinilla F. Dietary omega-3 fatty acids normalize BDNF levels, reduce oxidative damage, and counteract learning disability after traumatic brain injury in rats. J Neurotrauma 2004, 21:1457-1467.
246. Yatsiv I., Grigoriadis N., Simeonidou C., et al. Erythropoietin is neuroprotective, improves functional recovery, and reduces neuronal apoptosis and inflammation in a rodent model of experimental closed head injury. FASEB J 2005, 19:1701-1703.
247. Yi J.H., Park S.W., Brooks N., et al. PPARgamma agonist rosiglitazone is neuroprotective after traumatic brain injury via anti-inflammatory and anti-oxidative mechanisms. Brain Res 2008, 1244:164-172.
248. Yu C.G., Geddes J.W. Sustained calpain inhibition improves locomotor function and tissue sparing following contusive spinal cord injury. Neurochem Res 2007, 32:2046-2053.
249. Yu C.G., Jimenez O., Marcillo A.E., et al. Beneficial effects of modest systemic hypothermia on locomotor function and histopathological damage following contusion-induced spinal cord injury in rats. J Neurosurg 2000, 93:85-93.
250. Yu C.G., Jagid J., Ruenes G., et al. Detrimental effects of systemic hyperthermia on locomotor function and histopathological outcome after traumatic spinal cord injury in the rat. Neurosurgery 2001, 49:152-158.
251. Yu C.G., Joshi A., Geddes J.W. Intraspinal MDL28170 microinjection improves functional and pathological outcome following spinal cord injury. J Neurotrauma 2008, 25:833-840.
252. Yune T.Y., Kim S.J., Lee S.M., et al. Systemic administration of 17beta-estradiol reduces apoptotic cell death and improves functional recovery following traumatic spinal cord injury in rats. J Neurotrauma 2004, 21:293-306.
253. Yune T.Y., Lee J.Y., Jung G.Y., et al. Minocycline alleviates death of oligodendrocytes by inhibiting pro-nerve growth factor production in microglia after spinal cord injury. J Neurosci 2007, 27:7751-7761.
254. Yune T.Y., Park H.G., Lee J.Y., et al. Estrogen-induced Bcl-2 expression after spinal cord injury is mediated through phosphoinositide-3-kinase/Akt-dependent CREB activation. J Neurotrauma 2008, 25:1121-1131.
255. Zang D.W., Cheema S.S. Leukemia inhibitory factor promotes recovery of locomotor function following spinal cord injury in the mouse. J Neurotrauma 2003, 20:1215-1222.
256. Zhou Y., Su Y., Li B., et al. Nonsteroidal anti-inflammatory drugs can lower amyloidogenic Abeta42 by inhibiting Rho. Science 2003, 302:1215-1217.